Literature DB >> 29987100

Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism.

Tracy A Williams1,2, Jacopo Burrello2, Leonardo A Sechi3, Carlos E Fardella4, Joanna Matrozova5, Christian Adolf1, René Baudrand4, Stella Bernardi6,7, Felix Beuschlein1,8, Cristiana Catena3, Michalis Doumas9, Francesco Fallo10, Gilberta Giacchetti11, Daniel A Heinrich1, Gaëlle Saint-Hilary12, Pieter M Jansen13, Andrzej Januszewicz14, Tomaz Kocjan15, Tetsuo Nishikawa16, Marcus Quinkler17, Fumitoshi Satoh18, Hironobu Umakoshi19, Jiří Widimský20, Stefanie Hahner21, Stella Douma22, Michael Stowasser13, Paolo Mulatero2, Martin Reincke1.   

Abstract

Unilateral primary aldosteronism is the most common surgically correctable form of endocrine hypertension and is usually differentiated from bilateral forms by adrenal venous sampling (AVS) or computed tomography (CT). Our objective was to compare clinical and biochemical postsurgical outcomes of patients with unilateral primary aldosteronism diagnosed by CT or AVS and identify predictors of surgical outcomes. Patient data were obtained from 18 internationally distributed centers and retrospectively analyzed for clinical and biochemical outcomes of adrenalectomy of patients with surgical management based on CT (n=235 patients, diagnosed from 1994-2016) or AVS (526 patients, diagnosed from 1994-2015) using the standardized PASO (Primary Aldosteronism Surgical Outcome) criteria. Biochemical outcomes were highly different according to surgical management approach with a smaller proportion in the CT group achieving complete biochemical success (188 of 235 [80%] patients versus 491 of 526 [93%], P<0.001) and a greater proportion with absent biochemical success (29 of 235 [12%] versus 10 of 526 [2%], P<0.001). A diagnosis by CT was associated with a decreased likelihood of complete biochemical success compared with AVS (odds ratio, 0.28; 0.16-0.50; P<0.001). Clinical outcomes were not significantly different, but the absence of a postsurgical elevated aldosterone-to-renin ratio was a strong marker of complete clinical success (odds ratio, 14.81; 1.76-124.53; P=0.013) in the CT but not in the AVS group. In conclusion, patients diagnosed by CT have a decreased likelihood of achieving complete biochemical success compared with a diagnosis by AVS.

Entities:  

Keywords:  adrenalectomy; aldosterone; hyperaldosteronism; prevalence; quality of life; renin

Mesh:

Substances:

Year:  2018        PMID: 29987100     DOI: 10.1161/HYPERTENSIONAHA.118.11382

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  28 in total

Review 1.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 2.  Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism-a Review.

Authors:  Finn Holler; Daniel A Heinrich; Christian Adolf; Benjamin Lechner; Martin Bidlingmaier; Graeme Eisenhofer; Tracy Ann Williams; Martin Reincke
Journal:  Curr Hypertens Rep       Date:  2019-09-03       Impact factor: 5.369

3.  Adrenalectomy for Primary Aldosteronism: Significant Variability in Work-Up Strategies and Low Guideline Adherence in Worldwide Daily Clinical Practice.

Authors:  Wessel M C M Vorselaars; Dirk-Jan van Beek; Diederik P D Suurd; Emily Postma; Wilko Spiering; Inne H M Borel Rinkes; Gerlof D Valk; Menno R Vriens
Journal:  World J Surg       Date:  2020-06       Impact factor: 3.352

Review 4.  MANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism.

Authors:  Gregory L Hundemer; Anand Vaidya
Journal:  Eur J Endocrinol       Date:  2020-12       Impact factor: 6.664

Review 5.  What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics.

Authors:  C Christofer Juhlin; Ozgur Mete; Jérôme Bertherat; Thomas J Giordano; Gary D Hammer; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2021-02-03       Impact factor: 3.943

Review 6.  Immunohistochemistry of the Human Adrenal CYP11B2 in Normal Individuals and in Patients with Primary Aldosteronism.

Authors:  Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Koshiro Nishimoto
Journal:  Horm Metab Res       Date:  2020-04-14       Impact factor: 2.936

Review 7.  Surgical approach to patients with primary aldosteronism.

Authors:  Catherine McManus; Jennifer H Kuo
Journal:  Gland Surg       Date:  2020-02

8.  Surgical Outcomes Among Primary Aldosteronism Patients Without Visible Adrenal Lesions.

Authors:  Davis Sam; Gregory A Kline; Benny So; Janice L Pasieka; Adrian Harvey; Alex Chin; Stefan J Przybojewski; Alexander A Leung
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

9.  Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism.

Authors:  Minna Soinio; Anna-Kaarina Luukkonen; Marko Seppänen; Jukka Kemppainen; Janne Seppänen; Juha-Pekka Pienimäki; Helena Leijon; Tiina Vesterinen; Johanna Arola; Eila Lantto; Semi Helin; Ilkka Tikkanen; Saara Metso; Tuomas Mirtti; Ilkka Heiskanen; Leena Norvio; Mirja Tiikkainen; Tuula Tikkanen; Timo Sane; Matti Välimäki; Celso E Gomez-Sanchez; Ilkka Pörsti; Pirjo Nuutila; Pasi I Nevalainen; Niina Matikainen
Journal:  Eur J Endocrinol       Date:  2020-12       Impact factor: 6.664

10.  Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling.

Authors:  Adina F Turcu; Richard Auchus
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.